LLY.BA Eli Lilly and Company
Company Analysis
Latest News
Eli Lilly Showcases Kisunla Data, Highlighting New Alzheimer's Blood Test Results
Eli Lilly began participating in the Alzheimer's Association International Conference (AAIC) in London today. The event runs from July 12-15. The company...
Eli Lilly Price Target Raised to $1,400 by JPMorgan on Strong GLP-1 Momentum
JPMorgan Chase & Co. increased its price target for Eli Lilly and Company to $1,400 from $1,300, maintaining an "overweight" rating on the stock. The new...
Eli Lilly expands Asia distribution, Cantor Fitzgerald hikes price target
Eli Lilly and Company partnered with DKSH Business Unit Healthcare to distribute pharmaceutical products in Hong Kong and Macau. This agreement expands on...
🟢 LLY.BA is trading 2.1% up today on the launch of Medicare GLP-1 Bridge program
Eli Lilly's stock is up 2.1% today at $34,600 following the launch of its Medicare GLP-1 Bridge program. • The program, effective July 1, 2026, significantly...
🔴 LLY.BA is trading 2.3% down today on profit-taking after recent gains
LLY.BA is trading 2.3% down at $33,220.00 as the stock pulls back following a period of strong momentum and no new company-specific news. • The move is...
🟢 LLY.BA is trading 0.9% up today after positive EU regulatory opinion for Jaypirca
LLY.BA is trading at $33660.00 (+0.90%) as sentiment remains constructive following a key regulatory milestone for Jaypirca in the European Union. • The EMA’s...
Eli Lilly Wins EU Backing for Jaypirca, Targeting Chronic Leukemia
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Eli Lilly’s leukemia drug, Jaypirca....
Lilly Unlocks Medicare's 14 Million Obesity Patients at $50 a Month — But Can Volume Overcome the Price Trade-Off?
Shares surged 6.4% to $33,100 (LLY.BA) as Eli Lilly detailed exactly how seniors will get its weight-loss drugs for just $50 a month starting July 1 — even as...
🟢 LLY.BA is trading 6.4% up today as Eli Lilly sets $50 Medicare copay for obesity drugs
LLY.BA is trading 6.4% up at $33100.00 after Eli Lilly announced that Medicare Part D beneficiaries will be able to access Zepbound and Foundayo for $50 per...
Eli Lilly details $50 Medicare weight-loss plan for Zepbound and Foundayo
Eli Lilly released details for its Medicare GLP-1 Bridge program starting July 1, 2026. This initiative provides Medicare Part D beneficiaries access to...
🟢 LLY.BA is trading 2.3% up today after $1.9B Abbisko deal and Centessa acquisition
LLY.BA is trading 2.3% up today at $31,600.00 following a string of bullish corporate developments, including a major R&D collaboration and strategic...
🟢 LLY.BA is trading 2.2% up today on news of a major R&D deal, Centessa acquisition completion, and AI investment
• Eli Lilly announced a significant R&D and licensing collaboration with China's Abbisko Therapeutics, potentially worth up to $1.9 billion, to develop novel...
🟢 Eli Lilly and Company is trading 2.03% up today after announcing a neurodegeneration partnership and Q3 dividend
Eli Lilly and Company is trading 2.03% up at $30,200.00, following significant company-specific developments. • The company announced a strategic collaboration...
🔴 Eli Lilly and Company is trading 2.8% down today as profit-taking extends multi-day slide
Eli Lilly and Company is trading 2.8% down at $28,780.00, extending a multi-day slide from $30,340.00 on June 15 as investors lock in recent gains. • No fresh...
Eli Lilly Jaypirca Cuts Leukemia Progression Risk 45%, Beating Standard Care
Eli Lilly announced positive results from its Phase 3 BRUIN CLL-322 trial for Jaypirca (pirtobrutinib). Adding Jaypirca to a standard treatment of venetoclax...
Lilly Advances AJX-101, Showing Success in Treatment-Resistant Myelofibrosis Patients
Eli Lilly and Company reported Phase 1 data for its investigational type II JAK2 inhibitor at the 2026 European Hematology Association (EHA) Annual Meeting....